Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DNLI Denali Therapeutics	$13.89 -1.4%	$14.32	$10.57 ▼ $33.33	$2.02B	1.33	1.12 million shs	1.53 million shs
MIRM Mirum Pharmaceuticals	$50.34 -0.9%	$44.31	$32.00 ▼ $54.23	$2.49B	0.95	480,875 shs	737,624 shs
SDGR Schrodinger	$20.46 -2.8%	$23.72	$16.60 ▼ $28.47	$1.50B	1.64	904,558 shs	1.40 million shs
URGN Urogen Pharma	$14.65 -1.5%	$8.99	$3.42 ▼ $18.15	$675.51M	0.4	1.04 million shs	3.39 million shs

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DNLI Denali Therapeutics	0.00%	-4.54%	+3.50%	-5.89%	-38.62%
MIRM Mirum Pharmaceuticals	0.00%	+1.43%	+14.41%	+7.06%	+57.07%
SDGR Schrodinger	0.00%	-4.53%	-4.39%	-10.07%	+8.95%
URGN Urogen Pharma	0.00%	+21.78%	+249.64%	+23.11%	-11.27%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DNLI Denali Therapeutics	4.3665 of 5 stars	4.5	1.0	4.7	2.7	2.5	0.0
MIRM Mirum Pharmaceuticals	3.8738 of 5 stars	3.6	1.0	4.2	2.5	1.7	0.6
SDGR Schrodinger	1.9273 of 5 stars	3.5	1.0	0.0	1.1	2.5	0.6
URGN Urogen Pharma	4.7037 of 5 stars	4.5	4.0	4.5	2.9	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DNLI Denali Therapeutics	3.06	Buy	$33.71	142.72% Upside
MIRM Mirum Pharmaceuticals	3.13	Buy	$65.50	30.12% Upside
SDGR Schrodinger	3.00	Buy	$32.80	60.31% Upside
URGN Urogen Pharma	3.00	Buy	$32.86	124.28% Upside

Current Analyst Ratings Breakdown

Latest URGN, MIRM, SDGR, and DNLI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/16/2025	URGN Urogen Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$50.00
6/13/2025	URGN Urogen Pharma	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Neutral ➝ Neutral	$16.00
6/13/2025	URGN Urogen Pharma	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform ➝ Buy	$31.00
6/13/2025	URGN Urogen Pharma	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
6/13/2025	URGN Urogen Pharma	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Outperform ➝ Sector Outperform	$23.00 ➝ $47.00
6/13/2025	URGN Urogen Pharma	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $30.00
6/12/2025	URGN Urogen Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
6/3/2025	URGN Urogen Pharma	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$36.00 ➝ $10.00
5/23/2025	URGN Urogen Pharma	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$40.00 ➝ $15.00
5/22/2025	URGN Urogen Pharma	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$16.00 ➝ $3.00
5/19/2025	DNLI Denali Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$28.00 ➝ $27.00

(Data available from 6/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DNLI Denali Therapeutics	$330.53M	6.11	N/A	N/A	$8.53 per share	1.63
MIRM Mirum Pharmaceuticals	$336.89M	7.40	N/A	N/A	$4.70 per share	10.71
SDGR Schrodinger	$207.54M	7.23	N/A	N/A	$5.78 per share	3.54
URGN Urogen Pharma	$90.40M	7.47	N/A	N/A	($0.21) per share	-69.76

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DNLI Denali Therapeutics	-$422.77M	-$2.67	N/A	N/A	N/A	N/A	-35.90%	-32.41%	7/30/2025 (Estimated)
MIRM Mirum Pharmaceuticals	-$87.94M	-$1.61	N/A	N/A	N/A	-20.39%	-33.63%	-11.50%	8/6/2025 (Estimated)
SDGR Schrodinger	-$187.12M	-$2.63	N/A	N/A	N/A	-83.39%	-44.74%	-26.29%	7/30/2025 (Estimated)
URGN Urogen Pharma	-$126.87M	-$3.18	N/A	N/A	N/A	-150.68%	-97,487.15%	-49.57%	8/12/2025 (Estimated)

Latest URGN, MIRM, SDGR, and DNLI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	MIRM Mirum Pharmaceuticals	-$0.35	-$0.30	+$0.05	-$0.30	$98.47 million	$111.59 million
5/12/2025	Q1 2025	URGN Urogen Pharma	-$0.83	-$0.92	-$0.09	-$0.92	$22.71 million	$20.25 million
5/7/2025	Q1 2025	SDGR Schrodinger	-$0.81	-$0.82	-$0.01	-$0.82	$54.60 million	$59.55 million
5/6/2025	Q1 2025	DNLI Denali Therapeutics	-$0.71	-$0.78	-$0.07	-$0.78	$3.24 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DNLI Denali Therapeutics	N/A	N/A	N/A	N/A	N/A
MIRM Mirum Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SDGR Schrodinger	N/A	N/A	N/A	N/A	N/A
URGN Urogen Pharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DNLI Denali Therapeutics	N/A	9.56	9.56
MIRM Mirum Pharmaceuticals	1.32	3.22	3.04
SDGR Schrodinger	N/A	3.45	3.45
URGN Urogen Pharma	4.77	5.65	5.47

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DNLI Denali Therapeutics	92.92%
MIRM Mirum Pharmaceuticals	N/A
SDGR Schrodinger	79.05%
URGN Urogen Pharma	91.29%

Insider Ownership

Company	Insider Ownership
DNLI Denali Therapeutics	12.50%
MIRM Mirum Pharmaceuticals	22.87%
SDGR Schrodinger	8.60%
URGN Urogen Pharma	5.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DNLI Denali Therapeutics	430	145.28 million	127.12 million	Optionable
MIRM Mirum Pharmaceuticals	140	49.53 million	38.21 million	Optionable
SDGR Schrodinger	790	73.38 million	67.07 million	Optionable
URGN Urogen Pharma	200	46.11 million	43.76 million	Optionable

URGN, MIRM, SDGR, and DNLI Headlines

Recent News About These Companies

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGN

June 22 at 10:00 AM | prnewswire.com

Stocks With Rising Relative Price Strength: UroGen Pharma

June 20 at 1:38 PM | msn.com

HC Wainwright Has Negative View of Urogen Pharma Q2 Earnings

June 20 at 1:19 AM | americanbankingnews.com

Urogen Pharma (NASDAQ:URGN) Trading 10.3% Higher - Here's What Happened

June 18, 2025 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGN

June 18, 2025 | globenewswire.com

HC Wainwright Decreases Earnings Estimates for Urogen Pharma

June 18, 2025 | marketbeat.com

Urogen Pharma (NASDAQ:URGN) Raised to "Buy" at HC Wainwright

June 18, 2025 | americanbankingnews.com

H.C. Wainwright Sees Billion Dollar Potential in UroGen’s New Therapy

June 17, 2025 | msn.com

UroGen Pharma (NASDAQ:URGN) Trading Down 7.7% - Time to Sell?

June 17, 2025 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGN

June 17, 2025 | prnewswire.com

UroGen Pharma Ltd. (NASDAQ:URGN) Short Interest Down 29.9% in May

June 17, 2025 | marketbeat.com

UroGen Pharma (NASDAQ:URGN) Sees Strong Trading Volume on Analyst Upgrade

June 17, 2025 | americanbankingnews.com

URGN SHAREHOLDER ALERT: BFA Law Reminds UroGen Pharma Ltd. Investors of Upcoming July 28 Class Action Deadline - Contact The Firm if You Suffered Losses

June 16, 2025 | accessnewswire.com

Investors who lost money on UroGen Pharma Ltd.(URGN) should contact Levi & Korsinsky about pending Class Action - URGN

June 16, 2025 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors With Losses on Their Investment in UroGen Pharma Ltd. of Class Action Lawsuit And Upcoming Deadlines - URGN

June 16, 2025 | accessnewswire.com

UroGen Pharma (NASDAQ:URGN) Sees Large Volume Increase Following Analyst Upgrade

June 16, 2025 | marketbeat.com

Lost Money on UroGen Pharma Ltd. (URGN)? Contact Levi & Korsinsky Before July 28, 2025 to Join Class Action

June 16, 2025 | accessnewswire.com

URGN Investors Have Opportunity to Lead UroGen Pharma Ltd. Securities Fraud Lawsuit with the Schall Law Firm

June 16, 2025 | prnewswire.com

Did You Lose Money on UroGen Pharma Ltd. (URGN)? Levi & Korsinsky Urges Investors to Act Before July 28, 2025

June 16, 2025 | accessnewswire.com

UroGen Pharma (NASDAQ:URGN) Stock Rating Upgraded by HC Wainwright

June 16, 2025 | marketbeat.com

URGN SHAREHOLDER REPORT: UroGen Pharma Ltd. was Sued for Fraud – Investors with Losses are Notified to Contact BFA Law by July 28 Court Deadline (NASDAQ:URGN)

June 16, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

URGN, MIRM, SDGR, and DNLI Company Descriptions

Denali Therapeutics NASDAQ:DNLI

$13.89 -0.20 (-1.42%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$13.99 +0.10 (+0.69%)

As of 06/20/2025 05:08 PM Eastern

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Mirum Pharmaceuticals NASDAQ:MIRM

$50.34 -0.46 (-0.91%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$50.37 +0.03 (+0.06%)

As of 06/20/2025 04:52 PM Eastern

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.

Schrodinger NASDAQ:SDGR

$20.46 -0.59 (-2.80%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$20.66 +0.20 (+0.98%)

As of 06/20/2025 07:57 PM Eastern

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.

Urogen Pharma NASDAQ:URGN

$14.65 -0.22 (-1.48%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$14.73 +0.08 (+0.54%)

As of 06/20/2025 07:59 PM Eastern

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time